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Background: The bacille Calmette—Gue´rin (BCG) vaccine is a widely practiced vaccine, which is
useful for prophylaxis against tuberculosis. DisseminatedBCG infection (BCG-osis) is oneof themost
important complications of this vaccine and can be seen in patients with an underlying immuno-
deficiency. This studywasperformed todetermine the underlyingdefects in patientswithBCG-osis.
Methods: Immunological evaluation was performed in all children who developed BCG-osis after
vaccination in Tabriz, Iran.
Results: BCG-osis was documented in eight patients following vaccination. Axillary adenitis was
detected in seven patients, and hepatosplenomegaly was also found in seven patients. Immuno-
logical studies revealed low serum IgG, IgM and IgA levels in all patients. Further investigations for
enumerationof the lymphocyte sub-population revealed severecombined immunodeficiency (SCID)
in all the patients. Three patients had TB+NK SCID, four had TBNK+ SCID, and one had
TB+NK+ SCID. Unfortunately, all the patients died due to the severe disseminated BCG infection.
Conclusions: Inoculation of live vaccines such as BCG should be postponed for a few months in
suspected cases of primary immunodeficiency disease, until appropriate screening tests exclude
this diagnosis; vaccination should then be performed in those with an intact immune system.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
The bacille Calmette—Gue´rin (BCG) vaccine is widely prac-
ticed in many countries for prophylaxis against tuberculosis
(TB), especially in the pediatric age group. Although it is* Corresponding author. Tel.: +98 411 334 0533;
fax: +98 411 526 2280.
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doi:10.1016/j.ijid.2009.02.008considered safe in general, there are several complications,
ranging from regional disease (BCG-itis) to disseminated
disease (BCG-osis). However, BCG-osis, which is associated
with a highmortality rate, is very rare. This BCG complication
may suggest an underlying immunodeficiency.1—6
Primary immunodeficiency diseases (PID) are a heteroge-
neous group of disorders, characterized by an increased
susceptibility to infections.7,8 It appears that a number of
PID result in an increased susceptibility to severe mycobac-
terial disease following vaccination with BCG, includingPublished by Elsevier Ltd. All rights reserved.
Figure 1 The pedigrees of two families with disseminated BCG
and severe combined immunodeficiency (open shapes represent
healthy individuals, filled shapes represent affected patients,
small filled shapes represent stillbirth, and shapes with slashes
represent deceased individuals; boxes: males, circles: females).
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matous disease (CGD), and Mendelian susceptibility to myco-
bacterial diseases (e.g., IFN-g receptor 1/2 deficiencies, IL-
12/23 receptor b1 chain deficiency, IL-12p40 deficiency,
STAT1 deficiency, LZ-NEMO deficiency).8—15
This study was performed in order to determine the
underlying defects in patients referred to the Children’s
Hospital due to BCG-osis.
Patients and methods
This was a prospective study on children who developed
disseminated BCG after vaccination in Tabriz (East Azerbai-
jan, Iran). The study was approved by the local ethics
committee of the Tabriz Children’s Hospital. Eight patients,
who had BCG-osis, were referred to the Tabriz Children’s
Hospital, the main referral hospital in Tabriz, and an immu-
nological evaluation was performed in all these patients.
All of the study patients had been inoculated with the BCG
vaccine at birth, and clinical and laboratory findings of the
patients were compatible with a diagnosis of disseminated
BCG. They had two or more signs and symptoms of a systemic
syndrome compatible with mycobacterial disease, including
fever, weight loss, lymphadenopathy, cutaneous abscesses,
pneumonia, osteomyelitis, hepatomegaly, and splenomegaly.
Evidence of BCG infection was also confirmed by histopatho-
logic findings of acid-fast bacilli at two or more anatomic
sites (e.g., lymph nodes) outside the region of vaccination, in
gastric aspiration or in bone marrow aspiration.5
After taking themedical history and physical examination,
further laboratory investigations were performed to deter-
mine the underlying defects. Consanguineous marriage was
defined as partners who have at least one ancestor in com-
mon, with the ancestor being no more distant than a great
great grandparent. For descendants of the same generation,
a consanguineous marriage would be between one person and
a third cousin or a closer relative.16
In these patientswith confirmeddisseminatedBCG, screen-
ing laboratory tests, including complete blood count and
differential count (platelet volume, absolute lymphocyte
count, neutrophil and eosinophil counts), tests for HIV, and
serum immunoglobulin levels (IgG, IgM and IgA) were evalu-
ated. As the results suggested SCID, lymphocyte subpopula-
tions including CD19+ B-cells, CD3+ T-cells, CD56+ natural
killer (NK) cells, and also CD3+CD4+ and CD3+CD8+ T-cells
were measured by double staining of lysed whole blood fol-
lowedbyflowcytometric analysis. Other screening tests (e.g.,
nitroblue tetrazolium (NBT) for CGD) were not done as the
diagnosis of SCID had been confirmed at this point.
SCID was sub-classified based on the different peripheral
lymphocyte immunophenotyping as follows: TBNK+ SCID
(absent circulating T- and B-cells, but NK cells present),
TB+NK (absent circulating T- and NK cells, but B-cells
present), and TB+NK+ (absent circulating T-cells, but B- and
NK cells present).6,12
Results
Disseminated BCG infection was documented in eight
patients (four male and four female) following routine BCG
immunization. All patients were vaccinated at birth and weresubsequently complicated with BCG-osis. The parents of six
cases were consanguine. A family history of early onset
severe infections leading to death in infancy was documented
in three families (Table 1). As shown in Figure 1, the pedigree
of P1 shows the family of a SCID patient whose parents were
consanguine. There was a history of stillbirth in this family,
but evaluation for SCID had not been performed for the
stillbirth. The pedigree of P2 shows the family of a SCID
patient from non-consanguine parents. There was history of
early death due to severe infections in his sibling and his
cousin, but evaluation for SCID had not been performed for
those cases.
Axillary adenitis was detected in seven cases (all except
P2), while seven patients (all except P4) had hepatospleno-
megaly at the time of admission. In addition to BCG infection,
seven cases (all except P3) suffered from candidiasis; P2 and
P8 had diffuse candidiasis and the others had oral candidiasis.
Acid-fast bacilli were detected in the lymph nodes of
seven patients, all except P2 who did not have lymphadeno-
pathy. Seven cases experienced recurrent diarrhea. Gastric
aspiration also showed acid-fast bacilli in patients P1, P2, P3
and P8. Two patients (P2 and P4) had arthritis; patient P4 had
tuberculosis osteitis. Bone marrow aspiration also demon-
strated acid-fast bacilli. Moreover four cases experienced
severe pneumonia (P1, P4, P6, P7), but specific organisms
were not identified. Patient P4 also presented with pleural
effusion and patient P6 was complicated with eye involve-
ment, which led to blindness.
Immunoglobulin serum levels were measured as the first
screening test for PID. All had low serum IgG, IgM and IgA.











Absolute count (cells/mm3) SCID diagnosis
CD19 CD3 CD4 CD8 CD56
P1 29 9 8 5.7 0.627 (11%) 31 31 25 113 439 TBNK+
P2 70 23 11 9.5 0.570 (6%) 143 11 11 34 0 TB+NK
P3 180 270 13 6.2 1.488 (24%) 1220 30 15 30 60 TB+NK
P4 0 0 0 5.2 1.404 (27%) 0 154 112 42 491 TBNK+
P5 220 29 8 9.9 4.158 (42%) 1455 1122 499 624 499 TB+NK+
P6 211 34 26 5.94 2.079 (35%) 83 520 83 478 1309 TBNK+
P7 181 31 36 9.8 0.323 (3.3%) 55 13 10 16 191 TBNK+
P8 50 15 0 8.3 3.652 (44%) 1169 1460 475 584 183 TB+NK
BCG, bacille Calmette—Gue´rin; WBC, white blood cell; SCID, severe combined immunodeficiency; T, T-cell; B, B-cell; NK, natural killer cell.
Table 1 Characteristics of the patients with disseminated BCG








P1 Male 4 6 Yes No
P2 Male 4 4 No Yes
P3 Female 5 5 No No
P4 Female 5 5 Yes Yes
P5 Female 5 7 Yes Yes
P6 Male 4 4 Yes No
P7 Female 4 4 Yes No
P8 Male 6 7 Yes No
BCG, bacille Calmette—Gue´rin.
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sub-populations revealed SCID in all these patients (Table 2).
Among them, three had TB+NK SCID, four had TBNK+
SCID, and one had TB+NK+ SCID (Table 2).
Unfortunately, all the patients died due to severe disse-
minated BCG infection.
Discussion
In this study, all patients with BCG-osis had SCID. BCG-osis is
one of the most common causes of death in PID patients,
particularly in those with SCID.8 SCID is a heterogeneous
group of diseases that affects cellular and humoral immune
function and can be categorized into different groups with
different underlying genetic defects.7 Based on the pre-
sence of B-cells, SCID can be categorized into two groups,
TB+ SCID and TB SCID. These can subsequently be
divided into two subgroups based on the presence of NK
cells.
The underlying genetic defects in SCID are not always
reported, but it appears that all types of SCID are susceptible
to BCG.13 Although molecular studies were not performed in
these patients, gc deficiency (P3 and P8) and JAK3 deficiency
(P2) could be suspected in the patients with TB+NK SCID,
according to the associated phenotypic abnormalities. CD3,
CD45 and IL7-Ra deficiencies could be suspected in the
patient with TB+NK+ SCID (P5), while RAG1/2 and Artemis
deficiencies could be suspected in the patients with
TBNK+ SCID (P1, P4, P6 and P7).Apart from the type of SCID and the underlying genetic
defect, patients with SCID are susceptible to the majority of
microorganisms and life-threatening opportunistic infections
in early infancy.10,13,17 Several cases with SCID develop com-
plications after BCG vaccination, with BCG-osis and even
death occurring in some of them.9,17,18
It is commonly advised that the first dose of BCG vaccine
be administered at birth, particularly in regions with a higher
incidence of TB. It is estimated that the incidence of new
smear-positive tuberculosis in Iran is 24 per 100 000 popula-
tion countrywide,19 while the notification rate increases up
to 135 per 100 000 population in eastern Iran, neighboring
Afghanistan.20 Although the vaccine can prevent severe and
disseminated forms of tuberculosis, such as meningitis and
miliary TB, there is some controversy surrounding its protec-
tive efficacy against pulmonary TB.21
There was a positive family history of early death due
to recurrent infections in some patients, which should
be considered an alarm for PID. However, properly
assessing for family history of neonatal deaths and recur-
rent infections is not easy for front-line healthcare provi-
ders, and there are inherent difficulties in relying on
history. Consanguinity is another important issue in the
family history that was reported in six families in this
study; the resulting children are prone to autosomal
recessive congenital disorders. The rate of consanguineous
marriage in Iranian SCID patients is more than 80%, much
higher than the rate in the normal population and also in
other PID.8 Due to this high consanguinity rate in the
region, providing facilities for genetic counseling and
Disseminated BCG in children with SCID, Iran e423reproductive risk assessment, as well as public education
programs are recommended.16
While the BCG vaccine is routinely given to all Iranian
children at birth, this vaccine should be prohibited in some
specific PID cases, especially SCID, and also in their families
whomay have PID.11 Considering the high incidence of SCID in
northwestern Iran,8,22 delaying BCG vaccination for a few
months could be suggested in those families with a history of
recurrent infections or early death; however, vaccination
should definitely be performed later in those cases with an
intact immune system. Following this policy, several SCID
patients will not be vaccinated with BCG, while several cases
will still be missed. With regard to the difficulty in imple-
menting such a guideline in settings where BCG is given to all
newborns, changing the worldwide policy, or at least the
regional program of BCG vaccination from birth to 4 or 6
months could help healthcare workers to investigate under-
lying disease; SCID patients usually become symptomatic
during this period. However, a further worldwide survey is
needed to make the best decision on this issue.
Unfortunately, the prognosis for children with SCID is very
poor in Iran. Recent reports indicate that all Iranian SCID
patients die during the first year of life.8,10 Stem cell trans-
plantation is the only curative treatment in this group of
patients, however there are only a few centers for stem cell
transplantation in Iran, and these do not have enough experi-
ence to undertake transplantation in primary immunodefi-
ciency diseases. Delay in diagnosis and late referral of
patients is another reason why stem cell transplantation
has not been successful in the country.8
SCID patients have an increased susceptibility to myco-
bacterium infection and primarily to BCG vaccine.13 It is
recommended that inoculation of live vaccines such as
BCG should be postponed in those newborns of families with
a history of recurrent infections or early death, until appro-
priate screening tests exclude a diagnosis of PID. Further
epidemiological studies are needed to estimate the rate of
disseminated BCG infection in the region, while worldwide
studies on disseminated BCG and SCID may be worthwhile in
order to prepare guidelines on this topic.
Conflict of interest: No conflict of interest to declare.
References
1. Casanova JL, Jouanguy E, Lamhamedi S, Blanche S, Fischer A.
Immunological conditions of children with BCG disseminated
infection. Lancet 1995;346:581.
2. Cohn DL. Use of the bacille Calmette—Gue´rin vaccination for the
prevention of tuberculosis: renewed interest in an old vaccine.
Am J Med Sci 1997;313:372—6.
3. Gonzalez B, Moreno S, Burdach R, Valenzuela MT, Henriquez A,
Ramos MI, et al. Clinical presentation of Bacillus Calmette—
Gue´rin infections in patients with immunodeficiency syndromes.
Pediatr Infect Dis J 1989;8:201—6.
4. Casanova JL, Blanche S, Emile JF, Jouanguy E, Lamhamedi S,
Altare F, et al. Idiopathic disseminated bacillus Calmette—
Gue´rin infection: a French national retrospective study. Pedia-
trics 1996;98:774—8.
5. Afshar Paiman S, Siadati A, Mamishi S, Tabatabaie P, Khotaee G.
Disseminated Mycobacterium bovis infection after BCG vaccina-
tion. Iran J Allergy Asthma Immunol 2006;5:133—7.6. Deeks SL, Clark M, Scheifele DW, Law BJ, Dawar M, Ahmadipour
N, et al. Serious adverse events associated with bacille Calm-
ette—Gue´rin vaccine in Canada. Pediatr Infect Dis J
2005;24:538—41.
7. Geha RS, Notarangelo L, Casanova JL, Chapel H, Fischer A,
Hammarstrom L, et al. Primary immunodeficiency diseases: an
update the International Union of Immunological Societies Pri-
mary Immunodeficiency Diseases Classification Committee. J
Allergy Clin Immunol 2007;120:776—94.
8. Rezaei N, Aghamohammadi A, Moin M, Pourpak Z, Movahedi M,
Gharagozlou M, et al. Frequency and clinical manifestations of
patients with primary immunodeficiency disorders in Iran:
update from the Iranian Primary Immunodeficiency Registry. J
Clin Immunol 2006;26:519—32.
9. Huang LH, Shyur SD, Weng JD, Shin-Chi. Huang FY, Tzen CY.
Disseminated cutaneous bacille Calmette—Gue´rin infection
identified by polymerase chain reaction in a patient with X-
linked severe combined immunodeficiency. Pediatr Dermatol
2006;23:560—3.
10. Yeganeh M, Heidarzade M, Pourpak Z, Parvaneh N, Rezaei N,
Aghamohammadi A, et al. Severe combined immunodeficiency: a
cohort of forty patients. Pediatr Allergy Immunol 2008;19:303—6.
11. Movahedi M, Aghamohammadi A, Rezaei N, Shahnavaz N, Jan-
daghi AB, Farhoudi A, et al. Chronic granulomatous disease: a
clinical survey of 41 patients from the Iranian primary immuno-
deficiency registry. Int Arch Allergy Immunol 2004;134:253—9.
12. Bustamante J, Aksu G, Vogt G, de Beaucoudrey L, Genel F,
Chapgier A, et al. BCG-osis and tuberculosis in a child with
chronic granulomatous disease. J Allergy Clin Immunol
2007;120:32—8.
13. Reichenbach J, Rosenzweig S, Doffinger R, Dupuis S, Holland SM,
Casanova JL. Mycobacterial diseases in primary immunodeficien-
cies. Curr Opin Allergy Clin Immunol 2001;1:503—11.
14. Filipe Santos O, Bustamante J, Chapgier A, Vogt G, de Beaucou-
drey L, Feinberg J, et al. Inborn errors of the IL-12/23 and IFN-
gamma mediated immunity: molecular, cellular and clinical
features. Semin Immunol 2006;18:347—61.
15. Moin M, Farhoudi A, Movahedi M, Rezaei N, Pourpak Z, Yeganeh
M. The clinical and laboratory survey of Iranian patients with
hyper-IgE syndrome. Scand J Infect Dis 2006;38:898—903.
16. Rezaei N, Pourpak Z, Aghamohammadi A, Farhoudi A, Movahedi
M, Gharagozlou M, et al. Consanguinity in primary immunode-
ficiency disorders; the report from Iranian primary immunode-
ficiency registry. Am J Reprod Immunol 2006;56:145—51.
17. Stephan JL, Vlekova V, Le Deist F, Blanche S, Donadieu J, De
Saint-Basile G, et al. Severe combined immunodeficiency: a
retrospective single-center study of clinical presentation and
outcome in 117 patients. J Pediatr 1993;123:564—72.
18. Abramowsky C, Gonzalez B, Sorensen RU. Disseminated bacillus
Calmette—Gue´rin infections in patients with primary immuno-
deficiencies. Am J Clin Pathol 1993;100:52—6.
19. Global tuberculosis control. World Health Organization reports
1996-2002. TB situation in the region: Islamic Republic of Iran.
Presented at the Meeting of National Managers of the Tubercu-
losis Control Programmes in the Eastern Mediterranean Region,
Rabat, June 17-19, 2003.
20. Khazaei HA, Rezaei N, Bagheri GR, Dankoub MA, Shahryari K,
Tahai A, et al. Epidemiology of tuberculosis in the southeastern
Iran. Eur J Epidemiol 2005;20:879—83.
21. Barreto ML, Pereira SM, Ferreira AA. BCG vaccine: efficacy and
indications for vaccination and revaccination. J Pediatr (Rio J)
2006;82:45—54.
22. Sadeghi Shabestari M, Maljaei SH, Baradaran R, Barzegar M,
Hashemi F, Mesri A, et al. Distribution of primary immunodefi-
ciency diseases in the Turk ethnic group, living in the north-
western Iran. J Clin Immunol 2007;27:510—6.
